Preclinical development

Interleukin-2 conjugate
#Autoimmune disease #Preclinical development #Therapeutic proteins #VALANX Biotech

Study proves efficacy of protein conjugate in autoimmune disease

VALANX Biotech has reported successful in vivo results in its lead programme VLX101 for the treatment of a range of autoimmune diseases. The findings demonstrate the potential of VLX101, a novel Interleukin-2 conjugate and the efficacy of the therapeutic approach. Protein drugs hold great… Read More

#News

Mouse in laboratory
#Animal models #Charles River #Preclinical development #Sanofi

New project hopes to reduce the use of animals in drug research

Charles River Laboratories has announced the launch of its Virtual Control Groups (VCG) initiative with Sanofi. The companies are working together to reduce animal usage by replacing selected control group animals with selected matched virtual control animals developed using retrospective datasets. The VCG collaboration… Read More

#News

Organoids
#Drug discovery #Human disease models #Organoids #Preclinical development #Webinar

Discover the latest innovations in organoid model development

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM… Read More

Webinar date:
Supported by HUB Organoids
#News

Organoids
#Drug discovery #Human disease models #Organoids #Preclinical development #Webinar

How are patient-derived organoids revolutionising drug discovery?

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM… Read More

Webinar date:
Supported by HUB Organoids
#News

Organoid
#Drug discovery #Human disease models #Organoids #Preclinical development #Webinar

Discover how organoids bridge the gap between the lab and clinic

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM… Read More

Webinar date:
Supported by HUB Organoids
#News

Organoid
#Drug discovery #Human disease models #Organoids #Preclinical development

From patient to petri dish: Replicating disease with patient-derived organoids

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models. These models often fail to accurately represent the intricate biology of human patients. This webinar explores how patient-derived organoids (HUB Organoids) are revolutionising drug discovery by overcoming these challenges. Read More

Webinar date:
Supported by HUB Organoids
#Webinars

Lab mouse
#Animal models #Animal testing #Charles River #Preclinical development

Charles River launches initiative to reduce animal testing

Charles River Laboratories International has launched its Alternative Methods Advancement Project (AMAP), an initiative focused on developing alternatives to reduce animal testing. The company has invested $200 million over the past four years to reduce the use of animal testing and has a five-year goal of… Read More

#News

Mouse in laboratory
#Bispecific therapeutics #Drug discovery #Human disease models #Mouse models #Preclinical development #Preclinical investigations #Toxicology

Case Study: Streamline preclinical drug discovery

A new Case Study is now available to download for free: ‘In Vivo Evaluation Of Bispecific-Cell Engager Efficacy & Safety‘. Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing… Read More

#News

#Bispecific therapeutics #Drug discovery #Human disease models #Mouse models #Preclinical development #Preclinical investigations #Toxicology

Streamline preclinical drug discovery: PBMC-humanised mouse models

Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform. In… Read More

#Resources

#ADME / Tox #Cell Science #Organoids #Preclinical development #Preclinical investigations #Toxicology

Beyond animal testing: The rise of organoids in toxicology research

Around 30% of drugs show adverse reactions during human clinical trials despite promising pre-clinical studies. One of the major causes of the high attrition rate is the poor predictive value of current preclinical models used in drug development. Traditional 2D cell cultures often fail to replicate the cellular… Read More

#News

Researchers in a lab
#Drug development #Gene therapy #iPSC #Preclinical development #Webinar

How iPSC derived cells can support drug and gene therapy development

DDW recently hosted a webinar ‘Discover how iPSC derived cells can be used to support the development of drug and gene therapies’, supported by DefiniGEN. The event outlined how iPSC derived cells can be used to advance the efficiency and efficacy of disease modelling and covered topics including functionality, modelling… Read More

#Exclusive Content

#Drug discovery #iPSC #Neurology #Preclinical development #Preclinical investigations

Case Study: How to generate publishable data in just 12 weeks

A new resource is now available to download for free from sponsors Bit Bio: ‘Speeding up neuroscience research: Generating publishable data in 12 weeks‘. In this Case Study you will learn: How Professor Deepak Srivastava’s lab at King’s College London are working to unpick the complex… Read More

#News

#Drug discovery #iPSC #Neurology #Preclinical development #Preclinical investigations

Speeding up neuroscience research: Generating publishable data in 12 weeks

In this Case Study you will learn: How Professor Deepak Srivastava’s lab at King’s College London are working to unpick the complex biology of neuronal synapses to help us better understand neurological disorders like schizophrenia. How the researchers in Professor Srivastava’s lab have been able to generate publishable data… Read More

#Resources

384-well microplate
#Assays #Aurora Microplates #Drug development #Drug discovery #Lab technology #Podcast #Preclinical development

Podcast: How the tools you use impact precision in the lab

The latest sponsored DDW Sitting Down With podcast is now available. It features Charles Powell, CEO of Aurora Microplates, discussing how the Aurora microplate has evolved to keep up with changing trends within research and development. The microplate is a seemingly simple tool, yet it has… Read More

#News

384-well microplate
#Assays #Aurora Microplates #Drug development #Drug discovery #Lab technology #Preclinical development

How the tools you use impact consistency and precision in the lab

The latest sponsored DDW Sitting Down With podcast features Charles Powell, CEO of Aurora Microplates, discussing how the microplate has evolved to keep up with changing trends within research and development. The microplate is a seemingly simple tool, yet it has a crucial role to play… Read More

#Podcasts

Colorectal cancer
#Bowel cancer #Cancer research #Cidara #ESMO #Immuno-oncology #Oncology #Preclinical development

Drug-Fc conjugates exhibit robust anti-tumour activity

A novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) exhibited robust anti-tumour activity in humanised mouse models of colorectal cancer at low doses, according to data presented at the ESMO Immuno-Oncology (IO) Annual Congress. “We are thrilled to be presenting promising preclinical data on our novel multi-specific… Read More

#Cancer Research #News